FIELD: chemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody to adrenomedullin or its antigen-binding fragment. This antibody or antigen-binding fragment thereof specifically binds to the N-terminal region (ac-1-21) of mature human ADM having the sequence YRQSMNNFQGLRSFGCRFGTC, represented as SEQ ID NO: 23, and has an affinity binding to ADM of at least 10-7 M. Pharmaceutical combination is also provided for use as a medicament for stabilizing the circulation and comprising an effective amount of said antibody or antigen-binding fragment thereof and a vasoconstrictor, for example catecholamine. Pharmaceutical combination is proposed for use as a medicament for controlling a fluid balance and comprising an effective amount of said antibody or antigen-binding fragment thereof and an intravenous fluid. Pharmaceutical combination is proposed for use as a medicament for the treatment of sepsis and comprising an effective amount of said antibody or antigen-binding fragment thereof and an antibody to TNF-alpha. Also provided is a pharmaceutical composition for regulating a patient's fluid balance comprising an effective amount of said antibody or antigen-binding fragment thereof and a pharmaceutically acceptable excipient.
EFFECT: pharmaceutical combination is provided for use as a medicament for the treatment of sepsis and comprising an effective amount of said antibody or antigen-binding fragment thereof and antibiotics.
14 cl, 24 dwg, 12 tbl, 11 ex
